Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference
Zogenix, a biopharmaceutical company focused on rare diseases, will feature its CEO, Stephen J. Farr, Ph.D., and CFO, Michael Smith, in a virtual fireside chat on August 10, 2021, at 10:30 AM ET during the BofA SMID Cap 2H21 Ideas Conference. The event will be webcast live and archived for 90 days on Zogenix's Investor Relations website. The company is known for its FDA-approved therapy, FINTEPLA, for Dravet syndrome, and is advancing additional programs in related rare diseases.
- None.
- None.
EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on Tuesday, August 10, 2021, at the BofA SMID Cap 2H21 Ideas Conference.
| Zogenix Fireside Chat Details | |
| Date: | Tuesday, August 10, 2021 |
| Time: | 10:30 AM Eastern Time |
The fireside chat will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Trish McCall
Porter Novelli
+1 (805) 390-3279
trish.mcall@porternovelli.com
FAQ
What is the date of Zogenix's virtual fireside chat?
What time will Zogenix's fireside chat take place?
Who will represent Zogenix in the fireside chat?
Where can I watch the Zogenix fireside chat?
What is Zogenix's primary focus?
What is FINTEPLA and its significance to Zogenix?
